Table 2.
A priori regions | Mixed-effects analysis group × valence interaction | Pairwise comparisons: MDD > CON |
|
---|---|---|---|
Accept | Reject | ||
R amygdala | F(1, 305) = 17.91***, η2 = 0.06 | t(46) = 0.35, P = 0.73 | t(46) = 2.13, P = 0.04*, d = 0.62 |
L amygdala | F(1, 274) = 28.91***, η2 = 0.10 | t(46) = 1.26, P = 0.22 | t(46) = 2.21, P = 0.03*, d = 0.64 |
sgACC | F(1, 298) = 28.01***, η2 = 0.09 | t(46) = 0.32, P = 0.75 | t(46) = 3.06, P = 0.00**, d = 0.89 |
R anterior insula | F(1, 422) = 3.24, η2 = 0.01 | t(46) = 0.04, P = 0.97 | t(46) = 0.94, P = 0.35, d = 0.27 |
L anterior insula | F(1, 393) = 19.40***, η2 = 0.05 | t(46) = 0.13, P = 0.90 | t46) = 2.03, P = 0.05*, d = 0.59 |
R NAcc | F(1, 326) = 3.94, η2 = 0.01 | t(46) = 0.55, P = 0.59 | t(46) = 2.04, P = 0.05*, d = 0.59 |
L NAcc | F(1, 320) = 16.15***, η2 = 0.05 | t(46) = 0.10, P = 0.92 | t(46) = 2.47, P = 0.02*, d = 0.72 |
R VLPFC | F(1, 375) = 13.29***, η2 = 0.03 | t(46) = 0.32, P = 0.75 | t(46) = 1.68, P = 0.10, d = 0.50 |
L VLPFC | F(1, 408) = 11.29***, η2 = 0.03 | t(46) = 0.14, P = 0.89 | t(46) = 1.59, P = 0.12, d = 0.46 |
mPFC | F(1, 368) = 2.05, η2 = 0.01 | t(46) = 0.87, P = 0.39 | t(46) = 1.86, P = 0.07, d = 0.54 |
vACC | F(1, 314) = 8.36***, η2 = 0.03 | t(46) = 0.10, P = 0.92 | t(46) = 1.68, P = 0.10, d = 0.50 |
***P < 0.005 (Bonferroni corrected P-value for mixed effects F-tests), **P < 0.01, *P < 0.05; d, Cohen’s d effect size (0.20 = small, 0.50 = medium, 0.8 = large); η2, eta-squared effect size (0.01 = small, 0.06 = medium, 0.14 = large). ROI analyses were repeated excluding the two participants taking SSRI medications and all results were replicated, with the exception of the group × valence interaction effect in the vACC, which was no longer significant [F(1, 302) = 5.98, P = 0.02, η2 = 0.02].